Showing results (51-60 of 69) with videos related to
Sort By:
Pageof 7
Glia|May 4, 2013
UDP-glucose enhances outward K(+) currents necessary for cell differentiation and stimulates cell migration by activating the GPR17 receptor in oligodendrocyte precursorsElisabetta Coppi, Giovanna Maraula, Marta Fumagalli, et al.Frontiers in Pharmacology|May 10, 2018
The Selective Antagonism of Adenosine A<sub>2B</sub> Receptors Reduces the Synaptic Failure and Neuronal Death Induced by Oxygen and Glucose Deprivation in Rat CA1 Hippocampus <i>in Vitro</i>Irene Fusco, Filippo Ugolini, Daniele Lana, et al.Neurobiology of Aging|April 23, 2013
Amyloid-β oligomer synaptotoxicity is mimicked by oligomers of the model protein HypF-NFrancesca Tatini, Anna Maria Pugliese, Chiara Traini, et al.Neuropharmacology|November 10, 2024
MRS3997, a dual adenosine A<sub>2A</sub>/A<sub>2B</sub> receptor agonist, reduces brain ischemic damage and alleviates neuroinflammation in ratsIlaria Dettori, Irene Bulli, Martina Venturini, et al.American Journal of Physiology. Cell Physiology|July 24, 2009
Functional characterization of two isoforms of the P2Y-like receptor GPR17: [35S]GTPgammaS binding and electrophysiological studies in 1321N1 cellsAnna Maria Pugliese, Maria Letizia Trincavelli, Davide Lecca, et al.International Journal of Molecular Sciences|June 2, 2021
Role of Carbonic Anhydrase in Cerebral Ischemia and Carbonic Anhydrase Inhibitors as Putative Protective AgentsIrene Bulli, Ilaria Dettori, Elisabetta Coppi, et al.Journal of Medicinal Chemistry|March 24, 2009
Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studiesVittoria Colotta, Ombretta Lenzi, Daniela Catarzi, et al.Bioorganic & Medicinal Chemistry|May 13, 2008
Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonistsVittoria Colotta, Daniela Catarzi, Flavia Varano, et al.Neurobiology of Disease|August 29, 2016
Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington diseaseXavier Guitart, Jordi Bonaventura, William Rea, et al.Journal of Medicinal Chemistry|August 2, 2007
New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studiesVittoria Colotta, Daniela Catarzi, Flavia Varano, et al.Pageof 7